生物医药2026年度策略：十年创新，踏出海征程

Summary of Key Points from the Conference Call Industry Overview - The biopharmaceutical industry is experiencing significant growth, particularly in the CXO and chemical pharmaceutical sectors, with a notable increase in fund concentration in these areas [1][2] - The demand in the diagnostic and treatment sectors remains stable, and the medical insurance fund balance has significantly improved, indicating effective cost control measures [2][5] - The release of the first commercial insurance innovative drug directory in December 2025 has introduced new payment increments for the pharmaceutical industry [2][5] Financial Performance - In the first three quarters of 2025, the license-out transaction amount reached $92 billion, more than doubling year-on-year, indicating strong international recognition of domestic innovative drugs [2][6] - The IPO market in Hong Kong has rebounded, leading to increased investment activity in the primary market, with multiple pharmaceutical companies going public [2][6] Key Focus Areas for 2026 - The industry is expected to focus on innovative therapies, particularly IO (immune-oncology) bispecific antibodies and GLP-1 (glucagon-like peptide-1) drugs [1][4] - Notable advancements in the IO bispecific antibody field include the rapid development of Kangfang Biotech's PD-1/VEGF bispecific antibody AK112, with several key clinical data updates anticipated in 2026 [1][4][8] - Emerging technologies such as small nucleic acids and in vivo CAR-T are expected to show initial progress [4] GLP-1 Drug Market - The GLP-1 drug market shows immense potential, with Semaglutide leading in sales and Tirzepatide expected to become a new "blockbuster" [3][13] - There is a focus on new directions such as oral long-acting formulations and weight loss/muscle gain applications, with new targets like Amylin being explored [3][13][14] Investment Opportunities - The trend of innovative drugs going overseas is beneficial for industry chain enterprises, including major players like WuXi AppTec and WuXi Biologics, as well as CRO companies like InnoStar and Mediso [3][16] - The life sciences sector, including companies like BPS and Haoyuan, is also worth attention due to strong demand and performance certainty [16] Future Trends - The combination of IO and ADC (antibody-drug conjugates) is seen as a necessary direction for future development, with several companies already initiating clinical trials in this area [10][12] - The dual antibody drugs in the colorectal cancer field are becoming important assets for global pharmaceutical companies, indicating strong competitive potential for domestic products [9] Conclusion - The biopharmaceutical industry is poised for growth driven by innovation, with significant opportunities in both domestic and international markets. The focus on emerging technologies and the successful launch of innovative drugs will likely shape the industry's future landscape [1][4][16]